Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain

References

• Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–1568.
   PubMed Web of Science ®Google Scholar
• Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J. 2019;40(21):1707–1715.
   Google Scholar
• Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2016;68(2):161–172.
   PubMed Web of Science ®Google Scholar
• Reinés JB, Vera TR, Martín MU, et al. Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: son Llàtzer Hospital descriptive study. Orphanet J Rare Dis. 2014;9(1):29– 6.
   PubMedGoogle Scholar
• Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21–29.
   PubMed Web of Science ®Google Scholar
• Ohmori H, Ando Y, Makita Y, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet. 2004;41(4):1–5.
   PubMed Web of Science ®Google Scholar
• Zaros C, Genin E, Hellman U, et al. On the origin of the transthyretin val30met familial amyloid polyneuropathy. Ann Hum Genet. 2008;72(Pt 4):478–484.
   PubMedGoogle Scholar
• Olsson M, Jonasson J, Cederquist K, et al. Frequency of the transthyretin Val30Met mutation in the Northern Swedish population. Amyloid. 2014;21(1):18–20.
   PubMed Web of Science ®Google Scholar
• Kirov A, Sarafov S, Pavlova Z, et al. Founder effect of the Glu89Gln TTR mutation in the Bulgarian population. Amyloid. 2019;26(4):181–185.
   PubMed Web of Science ®Google Scholar
• Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in North West Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry. 1995;59(1):45–49.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Asl KH, Benson MD. A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy. Amyloid. 2000;7(1):46–50.
   PubMed Web of Science ®Google Scholar
• Niederhauser J, Lobrinus JA, Ochsner F, et al. Successful heart and liver transplantation in a swiss patient with Glu89Lys transthyretin amyloidosis. Transplantation. 2011;91(6):e40–e42.
   PubMed Web of Science ®Google Scholar
• Sandhu R, Westcott M, Pavesio C, et al. Retinal microangiopathy as an initial manifestation of familial amyloid cardiomyopathy associated with transthyretin E89K mutation. Retin Cases Brief Rep. 2013;7(3):271–275.
   PubMedGoogle Scholar
• Cruz S, Cortes-Vicente E, Illa I, et al. A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy. Amyloid. 2017;7(6):46–50.
   Google Scholar
• Bourque PR, McCurdy AR, Mielniczuk LM, et al. Cardiac amyloidosis phenotype associated with a Glu89Lys transthyretin mutation. Can J Cardiol. 2017;33(6):830.e5–830-e7.
   PubMed Web of Science ®Google Scholar
• Reynolds MM, Veverka KK, Gertz MA, et al. Ocular manifestations of familial transthyretin amyloidosis. Am J Ophthalmol. 2017;183:156–162.
   PubMed Web of Science ®Google Scholar
• Gawor M, Holcman K, Franaszczyk M, et al. Spectrum of transthyretin gene mutations and clinical characteristics of polish patients with cardiac transthyretin amyloidosis. Cardiol J. 2020. Online published.
   PubMedGoogle Scholar
• Álvarez Rubio J, Manovel Sánchez AJ, González-Costello J, et al. Characterization of hereditary transthyretin cardiac amyloidosis in Spain. Rev Esp Cardiol (English Edition). 2022;75(6):488–495.
   PubMed Web of Science ®Google Scholar
• Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3–9.
   PubMed Web of Science ®Google Scholar
• Gandolfo LC, Bahlo M, Speed TP. Dating rare mutations from small samples with dense marker data. Genetics. 2014;197(4):1315–1327.
   PubMed Web of Science ®Google Scholar
• Recaño VJ. La emigración andaluza en España. Bol Econ Andal. 1998;24:119–143.
   Google Scholar
• Instituto de Estadística y Cartografía de Andalucía. (Updated on 15/03/2021). https://www.juntadeandalucia.es/institutodeestadisticaycartografia/badea/operaciones/consulta/anual/6777?CodOper=b3_128&codConsulta=6777
   Google Scholar
• Lemos C, Coelho T, Alves-Ferreira M, et al. Overcoming artefact: anticipation in 284 portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85(3):326–330.
   PubMed Web of Science ®Google Scholar
• Cisneros-Barroso E, González-Moreno J, Rodríguez A, et al. Anticipation on age at onset in kindreds with hereditary ATTRV30M amyloidosis from the Majorcan cluster. Amyloid. 2020;27(4):254–258.
   PubMed Web of Science ®Google Scholar
• Gorram F, Olsson M, Alarcon F, et al. New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid. 2021;28(2):84–90.
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120–1127.
   PubMed Web of Science ®Google Scholar
• Monteiro C, Mesgazardeh JS, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4(12):e126526.
   PubMed Web of Science ®Google Scholar